DXC-006

DXC-006 is an investigational antibody-drug conjugate (ADC) developed by Hangzhou DAC Biotechnology. It targets neural cell adhesion molecule 1 (CD56), a cell surface molecule involved in cell-cell and cell-matrix adhesion that is overexpressed in several cancers, including neuroblastoma, small-cell lung cancer, and multiple myeloma. The ADC consists of an anti-CD56 antibody (DXA-006) linked to the topoisomerase 1 inhibitor CPT-116 via a chemical linker. Upon binding to CD56-expressing tumor cells, DXC-006 is internalized and releases its cytotoxic payload inside the cell, leading to targeted tumor cell death. The drug is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with advanced solid tumors and hematologic malignancies[2][5][7].